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Tumor necrosis factor receptor 2 (TNFR2) is a type I transmembrane glycoprotein and one of the two receptors that orchestrate the
complex biological functions of tumor necrosis factor (TNF, also designed TNF-𝛼). Accumulating experimental evidence suggests
that TNFR2 plays an important role in renal disorders associated with acute cellular rejection and clear cell renal carcinoma but its
exact role in these settings is still not completely understood. This papers reviews the factors that may mediate TNFR2 induction
in acute cellular rejection and clear cell renal carcinoma and its contribution to these conditions and discusses its therapeutic
implications. A greater understanding of the function of TNFR2 may lead to the development of new anti-TNF drugs.
1. Introduction
Tumor necrosis factor (TNF, also known as TNF-𝛼) is a type
II transmembrane protein with an intracellular aminoter-
minus. It can transduce signalling both as a membrane-
integrated protein and as a soluble cytokine released after
proteolytic cleavage; its soluble form is a noncovalently
bound trimer of 17 kDa components [1] and its transmem-
brane form is a functional 26-kDa homotrimer protein [2].
TNF is a major mediator of inflammatory, immunological,
and pathophysiological reactions [3]. TNF mediates various
cellular responses by binding to two structurally distinct
receptors: TNF receptor 1 (TNFR1; TNFRSF1A, CD120a, and
p55) and TNF receptor 2 (TNFR2; TNFRSF1B, CD120b, and
p75), members of the TNFR superfamily [4, 5]. TNFRs share
homology in their extracellular regions, containing cysteine-
rich structural motifs that form TNF-binding domains, but
have nonidentical intracellular domains resulting in nonover-
lapping functions. The affinities of both receptors for soluble
TNF are similar. In contrast to TNFR1, which belongs to
the subgroup of TNFR superfamily molecules that contain
a cytoplasmic death domain (DD), TNFR2 does not have
a DD and lacks the ability to directly activate the apoptotic
machinery through DD adaptors [6]. Compared to TNFR1,
which is detected on nearly all kinds of cells and predomi-
nantly sequestered in theGolgi apparatus [7], TNFR2 exhibits
far more limited expression and is typically localized to the
plasma membrane in epithelial cells of the distal collecting
tubules in acute transplant rejection [8], in T-lymphocytes
[9], cardiomyocytes [10], humanmesenchymal stem cells [11],
human andmurine cardiac resident stem cells [12], microglia
and specific neuron subtypes [13], oligodendrocytes [14],
and thymocytes [15]. Most biological responses have been
attributed to signalling initiated by TNFR1, but some
responses have been ascribed to ligand binding to TNFR2 [10,
16, 17]. Signal transduction through TNFR1 has been widely
studied over the past few years, whereas TNFR2 has proved
to be far more elusive in revealing its signal transduction
pathways, although recent evidence suggests that it plays an
essential role in cell proliferation and survival [9–11, 18, 19]
and in the activation of regulatory T cells [20, 21].
Kidney transplantation is the best choice for the treatment
of end-stage kidney disease but rejection is the major com-
plication after transplant resulting in graft loss. Acute cellular
rejection (ACR) involves the interplay between mechanisms
that maintain tolerance to the graft and factors that promote
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rejection [22]. Cytokines are potentmediators of alloimmune
response leading to ACR. Increased levels of TNF mRNA
are expressed in ACR and TNF protein is secreted primarily
by immune cells such as macrophages, lymphocytes, natural
killer cells, and nonlymphoid cells, for example, endothelial
cells (ECs) and tubular epithelial cells (TECs), and are
detected in rejecting kidney grafts [10, 23]. However, the roles
of TNFRs in the setting of ACR are yet still unclear.
Renal cell carcinoma (RCC), a TEC malignancy, is the
most common type of kidney cancer in adults, responsible for
approximately 80% of cases [24]. A clear cell renal carcinoma
(ccRCC) is the major subtype of RCC accounting for >80%
of all RCC types, while the other 20% comprise of papillary,
chromophobe, and oncocytic types [25]. RCC is relatively
resistant to conventional cancer treatments, such as radio-,
immuno-, and chemotherapy [26]. Although surgery and
cryoablation are successful curative treatments for local-
ized RCC, most patients are diagnosed with advanced or
metastatic RCC with poor prognosis. The aggressive nature
of RCC is reflected by recurrence rates of 20% to 40% after
nephrectomy [27]. The risk of renal transplantation patients
developing de novomalignancy is 100-fold increase compared
with the healthy nontransplantation population [28–30]. Up
to 4.6% of the renal transplant recipients are diagnosed
with RCC arising from allografted kidney as a consequence
of immunosuppression [29, 30]. Current staging systems
provide good prognostic information, however, identification
of new more accurate and predictive prognostic markers,
not currently included in traditional staging systems, will
improve the outcome for RCC patients. For this reason,
increased knowledge of the underlying molecular charac-
teristics of RCC development and progression is necessary.
The expression and anatomical distribution of the TNFRs is
certainly of great importance in trying to understand the
pathophysiology of TNF responses. TNFRs are differentially
expressed in normal kidney and their expression is modu-
lated during immune-mediated renal injury [8, 18] and in
ccRCC [16], with TNFR2 significantly induced in injured
and malignant TECs. In this review, we will discuss the
contribution of TNFR2 in ACR and ccRCC and its therapeu-
tic implications.
2. TNFR2 Signalling and Biological Responses
TNFR2 signaling pathways are illustrated in Figure 1. TNFR2
was initially believed to display modulating and supportive
functions to TNFR1, a process called “ligand passing” [31].
However, further characterization of the TNFRs usingTNFR-
specific muteins (mutant forms of TNF that engage exclu-
sively to TNFR1 or TNFR2 so are receptor-specific ligands)
or agonistic antibodies have led to the elucidation of different
signaling pathways engaged by the two TNFRs. TNFR2
is a main receptor for transmembrane TNF, which binds
more strongly to TNFR2 than does soluble TNF due to the
formation of a tight trimer that is unable to dissociate from
the receptor [32].
Transduction of extracellular signals by TNFR2 occurs
via recruitment of cytosolic proteins to its intracellular
domain as a result of the conformational changes induced
by ligand binding [32]. The ligand-bound TNFR2 initiates
signalling via direct binding to TNFR-associated factor 2
(TRAF2) [33]. TRAF1 and TRAF2 are associated with the
cytoplasmic domain of TNFR2 as a heterodimeric complex in
which only TRAF2 contacts the receptor directly. TNFR2 can
also recruit TRAF2 and activate the two cellular inhibitors of
apoptotic proteins (cIAP1 and cIAP2) [34].Theubiquitin pro-
tein ligase activity of c-IAP1 is responsible for regulating the
duration of TNF signaling in primary cells expressing TNFR2
[35]; however, the exact role of these factors in TNFR2-
specific signalling remains undefined. The TNFR2/TRAF2
complex provides amechanism for activation of transcription
factors such as nuclear factor-𝜅B (NF𝜅B) and the activator
protein 1 (AP-1) [36]. NF𝜅B is a critical transcription factor
that plays an important role in cell growth, survival, and
immune regulation. AP-1 is a heterodimeric transcription
factor, the most common form consisting of c-Jun and c-Fos
[37]. However, TNFR2 expressed at physiological levels fail to
induce significant NF𝜅B and c-Jun N-terminal kinase (JNK)
activation [38]. Only when over-expressed, TNFR2 can dis-
play NF𝜅B and JNK activation by TNF treatment [39]. Thus,
it appears that TNFR2 is aweak trigger ofNF𝜅B and JNKacti-
vation despite its high TRAF2 binding capability. This may
be attributed to a novel carboxyl-terminal TRAF2-binding
site (T2bs-C) that prevents the delivery of activation signals
from the conventional TRAF2 binding site (T2bs-N) [40].
However, others have reported that the C-terminal region
of TNFR2 responsible for the binding of TRAF2 is indis-
pensable for signal transduction and NF𝜅B activation [41].
Another mechanism by which TRAF2 can activate NF𝜅B
involves RIPK1 [42]. Indeed, rip−/− mice (lacking RIPK1)
shownoNF𝜅B activation in response toTNF, andTNFR2was
identified as the primary receptor that induced I𝜅B𝛼degrada-
tion, the initiating event in NF𝜅B activation [43]. In keeping
with this observation, neutralization of TNFR2 on podocytes
with blocking antibodies abrogated TNF-induced NF𝜅B acti-
vation and induced cyclin D1 instead [44]. Regardless of the
mechanism, the key point is that the activation of NF𝜅B
cannot be exclusively relied on as a marker for signalling
via TNFR2 as ligand-bound TNFR2 can activate NF𝜅B in
only some cell types. Following ligation of TNFR2, the down-
stream signaling effects can depend on which of the genes
NF𝜅B transcribes. Although the effect is most frequently pro-
liferation, it can include differentiation, cytokine production
and apoptosis. TNFR2 activation can induce cell death in
T lymphocytes [42]; however, the signalling pathway respon-
sible for this is still unclear although TNF can also kill other
cell types via TNFR2 activation when phosphatidylinositol 3
kinase (PI3K) is blocked [45], probably through necroptosis
[46]. TNFR2 can promote proliferation/survival in renal
tubular cells, renal tumor cells, and ECs via phosphorylation
of a cytosolic protein tyrosine kinase, belonging to the btk
family, also known as epithelial/endothelial tyrosine kinase
(Etk) in humans and as bone marrow X-linked kinase (Bmx)
in mice [10, 16, 18, 47]. TNFR2-induced activation of Etk
causes transactivation of vascular endothelial growth factor
receptor-2 (VEGFR2, also known as KDR or flk-1) [16,
47] resulting in activation of PI3K and its effector Akt, a
serine/threonine kinase also called protein kinase B or PKB,
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Figure 1: Intracellular tumour necrosis factor receptor-2 (TNFR2) signalling. Binding of tumour necrosis factor (TNF) to TNFR2 results
in activation and recruitment of intracellular adaptor proteins that induce signal transduction promoting cell proliferation and survival via
phosphorylation of endothelial/epithelial nonreceptor tyrosine kinase (Etkp40), which in turn transactivates vascular endothelial growth factor
receptor-2 (VEGFR2p1054−1059), leading to phosphatidylinositol 3-kinase (PI3K)-Akt/PKB pathway.
leading to cell proliferation/survival. Murine heart lacking
TNFR2 shows a diminished activation of Etk [10].Thus, phos-
phorylation of Etk may be useful to assess TNFR2 responses
in situ, where downstream signalling has been shown to
mediate reno- and cardioprotection [10, 18].
3. TNFR2 and ACR
TNF is a mediator of tissue injury associated with allograft
rejection after renal transplantation [48]. TNF gene poly-
morphism at position G/A-308 in donors with high levels of
TNF production is associated with a higher risk of rejection,
delayed graft function/survival in kidney transplant recipi-
ents [49, 50]. However, some reports fail to show an associa-
tion [51] and conflicting data exist as to whether serum/urine
TNF levels reflect reliably the rejection crisis [52]. The
effect of TNF on graft outcome is influenced by the diverse
range of cellular responses triggered by the two distinct
TNFRs, which lead to signalling cascades that induce expres-
sion of many genes involved in inflammation. TNFRs are
differentially expressed and regulated in normal human kid-
ney and in renal transplants undergoing ACR [8]. In contrast
to TNFR1, mainly present in glomerular and perivascular
capillaries ECs and in infiltrating leukocytes in human renal
allograft biopsies, TNFR2 is significantly induced in injured
TECs near TNF-expressing leukocytes and in ECs in humans
[8, 18] and rats [53] but barely detected in kidney of healthy
subjects and in normal rats. TNFR2 inducibility is supported
by its promoter region, which has a cAMP-response and
consensus elements for a number of transcription factors
includingNF𝜅B, AP-1, IRF, andGAS [54]. Interaction of TNF
and TNFR2 has been demonstrated in different models of
immune-mediated renal injury [10, 18, 53, 55]. In organ cul-
ture of normal human kidney and allograft rejection, selective
engagement of TNFR2 by a specific TNF mutein induces
TNFR2 protein and mRNA in TECs (Figure 2), suggesting
that the receptor is controlled at the level of gene transcription
[8, 10, 18, 56]. TNFR2 mRNA has a large 3󸀠 untranslated
region, which, in addition, may be important in regulation
of TNFR2 mRNA stability posttranscriptionally [57].
The induction of TNFR2 protein and mRNA in TECs in
allograft rejection strongly suggests that it is an important
receptor inmediating and/or regulating the rejection process.
TNFR2 has been shown to participate in the process of
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Figure 2: Tumour necrosis factor receptor-2 (TNFR2) mediated cellular responses in organ cultures of ACR. Treatment of cultures with
a TNFR2-selective mutein induces TNFR2 mRNA and protein in tubular epithelial cells (arrows) (a, b), which in turn activates and
phosphorylates epithelial/endothelial tyrosine kinase at tyrosine 40 (Etkp40) (c, d) promoting cell cycle entry, indicated by staining for
proliferative cell nuclear antigen (PCNA) (e).
xenograft rejection in pigs [58] and its soluble form acts as
a powerful immunosuppressant in alloreactivity [59]. How-
ever, the factors that mediate induction of TNFR2 in injured
TECs and its contribution to the process of rejection are
incompletely understood. Based on our work in human
organ cultures [10, 18, 56] and of other groups [44, 60],
we can postulate several possibilities as to the roles of
TNFR2 in ACR. The pathological changes in intragraft
microenvironment during development of allograft rejection
may promote/sustain TNFR2 expression in an autocrine
and/or paracrine manner. EC destruction/proliferation,
resulting from infiltration of alloimmune leukocyte- and/or
alloantibody-induced responses, leading to abnormal blood
flow and hypoxia in tissue [56, 61] may be important
contributors to TNFR2 expression/function in TECs [10, 56].
The effect of hypoxia on TNFR2 regulation has recently been
reported [12].
Renal TECs, the predominant parenchymal cell type in
the kidney and the principal target of renal injury, can
be induced to synthesize/secrete inflammatory mediators
including TNF, interleukin (IL)-6 and -10, interferon-𝛾 (IFN-
𝛾), and chemokines which mediate activation and recruit-
ment of leukocytes within the graft tissue as a hallmark
of allograft rejection [62–64]. The invading immune cells
including T- and B-lymphocytes, Tregs, and tissue-associated
macrophages (TAM) proliferate and are fully activated in situ
in tubulitis associated with ACR and may be instrumental in
inducing TNFR2 in TECs via production of TNF [8, 18].
Another factor that may regulate TNFR2 induction in
TECs is TNF-converting enzyme (TACE, also known as
ADAM-17) synthesized in situ by TECs and colocalizes
with TNFR2 during ACR [65]. TACE activity is regulated
primarily by controlling its localization. Inactive rhomboid
protein 2 (iRhom2), a proteolytically inactive member of the
rhomboid family, binds TACE and promotes its exit from the
endoplasmic reticulum [66], allowing it to traffic to the cell
surface. TACE regulates shedding of TNFR2 into the local
environment, which may attenuate inflammation caused by
TNF [65]. Indeed, changes in serum levels of TNFR2 correlate
significantly with renal transplant rejection [67] and renal
injury inmice [44].The soluble shedTNFR2,which is capable
of binding TNF, may neutralize TNF-induced cytotoxicity
and immune-reactivity thus downregulating inflammation in
vivo and in vitro [60].
Another important mediator of TNFR2 induction in
TECs is TL1A (TNFSF15; also known as VEGI), the principal
ligand for DR3 [56, 68]. TL1A is secreted and released by vas-
cular ECs and infiltrating leukocytes in acute and antibody-
mediated allograft rejection [56]. TECs expresses TL1A
protein but not its mRNA, consistent with its uptake as an
exogenous ligand by TECs [56]. In kidney organ cultures
fromDR3-deficientmice, TL1A induces TNFR2 upregulation
in TECs viaNF𝜅B-independent pathways [56]. Hence, leuko-
cyte/ECs-derived TL1A in allograft rejection may contribute
to the induction of TNFR2 in TECs in situ.
TNFR2 protein and mRNA can also be induced in organ
culture of renal allograft rejection treated with wild type TNF
or a TNFR2-selective mutein [18], resulting in phosphory-
lation of Etk. TNFR2-mediated Etk phosphorylation leads
to activation of the PI3K/Akt pathway providing a signal
for tubular regeneration by promoting cell proliferation
(indicated by expression of a cell cycle marker Proliferation
Cell Nuclear Antigen; PCNA) (Figure 2) [18, 47]. Indeed, in
vivo and in vitro studies using a TNFR2-specific mutein and
TNFR2-deficient cells have confirmed that Etk is a TNFR2-
specific kinase involved in cell adhesion, migration, and
survival [47]. Collectively, current data implicate TNFR2 in
ACR, albeit the causal connections remain to be revealed.
4. TNFR2 and ccRCC
RCC is typified by biallelic inactivation of the von Hippel-
Lindau (VHL) tumor suppressor gene [69]. A mutation
in VHL gene results in increased production of cytokines
including TNF, which sensitizes local tumor cells to TNF
actions. TNF is a major mediator of cancer-related inflam-
mation [70] and promotes tumor progression/metastasis [16]
through regulation of cytokines, adhesion molecules, metal-
loproteinases, and proangiogenic activities [71, 72]. Leuko-
cyte infiltration includes B- and T-lymphocytes and TAM
also produce TNFwhichmodulate, tumor growth [16, 73, 74].
Indeed, TNF-308 G/G genotypes are significantly higher in
patients with RCC compared with healthy controls [75].
Rarely detected in normal TECs, ccRCC, TNF, and TNFR2
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protein and mRNA are induced in malignant TECs and
infiltrating leukocytes, and TNFR2 increase correlates with
malignant/tumor grade [16]. Similarly, increased plasma lev-
els of soluble TNFR2 are detected in patients with metastatic
RCC and correlate with malignant grade [76].
In ccRCC organ cultures, a TNFR2-specific mutein
induce TNFR2 mRNA and protein comparable to responses
elicited by wild-type TNF, although somewhat higher con-
centrations of themutein are required to induce the very same
responses. TNFR2 induction in TECs in organ culture results
in a reciprocal coordinate activation of Etk, VEGFR2, and
NF𝜅B and promotes cell cycle entry (indicated by expression
of nuclear phospho-Histone H3𝑆10 and ki67) (Figure 3), lead-
ing to activation of the PI3K/Akt pathway [47]. ki67-positive
staining has been proposed as an independent prognostic
factor for RCC [77, 78]. TNF-mediated induction of cell
proliferation has also been reported in short-term established
RCC cell lines [79].
Signals induced byTNFR2 inmalignant TECs are distinct
from the signals induced by VEGFR2, as in contrast to TNF,
VEGF does not induce Etk activation or cell cycle entry [16].
Moreover, in ccRCC organ cultures, the downstream effects
of TNFR2 signaling occur at much lower concentrations of
TNF compared to TNFR1 signalling, consistent with in vitro
data [80]wherebyTNFR2 contribute to the effects of low con-
centrations of TNF, possibly serving to capture and pass TNF
to the less abundant signalling (TNFR1) receptor. The abso-
lute TNFR2 dependence of cell cycle entry inmalignant TECs
in ccRCC organ cultures using wild type TNF and a TNFR2-
selective mutein (but not TNFR1-selective mutein) clearly
supports an active signalling rather than a ligand-passing
function of TNFR1 [16]. The finding of TNFR2-dependent
induction of TNFR2 expression and transactivation of
Etk/VEGFR2 in malignant TECs is important as it implies
that TNFR2 may act as an autocrine growth factor in ccRCC.
In malignant TECs, TNFR2 may regulate gene induction of
antiapoptotic proteins via NF𝜅B activation which may halt
cell death. Indeed, lack of pVHL protein confers RCC cell
resistance to the cytotoxic effects of TNF, which is restored
upon reconstitution of the VHL protein, with a concordant
expression of NF𝜅B target anti-apoptotic genes such as A20,
c-FLIP, Survivin, c-IAP-1, and cIAP-2, blocking the activities
of caspases-8 and -3 [81].
Single nucleotide polymorphism (SNP) in the TNFR2
gene can predict outcome in other forms of cancer and
autoimmune disease [82–85]. A SNP changing T to G in exon
6 at nucleotide 676 of TNFR2mRNA that results in an amino
acid change in the fourth extracellular cysteine rich domain
from methionine (TNFR2196MET) to arginine (TNFR2196Arg)
has been associated with increased risk of chronic inflamma-
tory disorders [82, 84, 86]. Expression of the TNFR2196Arg
variant in geneticallymodified cells cause diminished recruit-
ment of TRAF2 to TNFR2196Arg resulting in impairment
of TNFR2-mediated NF-𝜅B activation and TNFR1-induced
cell death [86]. However, an association between TNFR2
gene polymorphism and ccRCC has not been reported.
We have, however, recently demonstrated TNF-mediated
induction of TNFR2 in tumor stem cells in ccRCC organ
cultures in association with increased cell cycle entry (RSL;
unpublished observations). Stem cells isolated from several
tumors have been implicated in malignant cell growth and
metastasis. Thus, it is not unreasonable to speculate that
TNFR2-induction in tumor stem cells may contribute to
population of TNFR2-expressing malignant TECs that may
be a crucial role in the growth and progression of ccRCC.
Alternatively, TNFR2-expressing malignant TECs may pro-
vide signals to initiate differentiation of tumor stem cells,
which play a role in tubular morphogenesis [87]. Collectively,
data from ccRCC organ cultures strongly suggest that TNFR2
in malignant TECs may sustain tumor growth and progres-
sion. Indeed, TNFR2 is essential for angiogenesis in murine
lung tumor xenografts, as its blockade lead to tumor regres-
sion [88].Moreover,mapping of TNFR2 to chromosome 1p36
revealed that nonrandom translocations occur near this locus
in some hematopoietic malignancies [89] and the 1p36 locus
has also been associated with malignant lymphoma, neurob-
lastoma, glioma, and non-Burkitt’s lymphoma [89, 90].
A model of the contribution of different cell populations
to the induction of TNFR2 in TECs in ACR and ccRCC is
presented in Figure 4.
5. Therapeutic Targeting of TNFR2 in
ACR and ccRCC
Anti-TNF drugs such as infliximab, etanercept, adalimumab,
certolizumabpegol, and golimumab have been used for treat-
ment and management of various autoimmune diseases [91–
93]; however they fail to show any favorable results in patients
with chronic heart failure [94]. So is there a role for anti-TNF
drugs in prevention of ACR and RCC? Little is known about
anti-TNF therapy in conjunction with antirejection and anti-
cancer in organ transplant recipients. A single-center study
evaluating the role of TNF inhibitors in kidney transplanta-
tion has been initiated but the results are not yet available
[95] and randomized clinical trials are still lacking. Anti-TNF
drugs show differential activity and efficacy [96]. For exam-
ple, infliximab (a chimeric monoclonal antibody) is more
effective than etanercept (a p75 TNF receptor/Fc fusion pro-
tein) in inhibiting the actions of transmembrane TNF rather
than soluble TNF by forming stable complexes [96]. The
superiority of transmembrane TNF in activating TNFR2 [97]
suggests that under certain conditions, infliximab may be
more effective at blocking signalling through TNFR2 than
etanercept. A lack of mechanistic understanding of disease
contributes to the failure of TNF antagonist. Thus, efforts
have been placed in dissecting the individual TNFR signalling
responses in an attempt to develop TNFR agonists instead.
Selective targeting of TNFR2 in type I diabetes has shown
better results than global TNF inhibition [98]. In additional,
systemic administration of a TNFR2 agonist to baboons
stimulate T cell proliferation without inflammation [99]. The
differential expression of TNFRs inACR and ccRCCprovides
a therapeutic rationale for developing drugs that target
individual receptors rather than targeting global TNF, which
might not yield the desired results as this would affect both
TNFRs, where TNFR1 signalling is detrimental in ACR while
TNFR2 is beneficial, but detrimental in ccRCC. Rather, a
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Figure 3: Tumour necrosis factor receptor-2 (TNFR2) mediated cellular responses in organ cultures of clear cell renal carcinoma
(ccRCC). Treatment of cultures with a TNFR2-selective mutein induce coordinated activation and phosphorylation of endothelial/epithelial
nonreceptor tyrosine kinase (Etkp40) and vascular endothelial growth factor receptor-2 (VEGFR2p1054−1059) in malignant tubular epithelial
cells (arrows) (a–i), promoting cell cycle entry (j), indicated by nuclei staining for phospho-Histone H3S10 (H3pS10) and NF𝜅Bp65 activation
(k).
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Figure 4: Diagram of postulated events and contribution of the different cell populations in human kidney tissue from biopsies with
acute cellular rejection (ACR) and clear cell renal carcinoma (ccRCC). Cytokines (TNF and TL1A) and TNFR2 protein/mRNA secreted
by endothelial cells (ECs) and infiltrating leukocytes (neutrophils, tissue-associated macrophages (TAM), and T- and B-lymphocytes) and
TNFR2mRNA and TNF-alpha converting enzyme (TACE) secreted by tubular epithelial cells (TECs) facilitate induction and upregulation of
TNFR2 in injured/malignant TECs via autocrine/paracrine mechanisms, promoting activation and phosphorylation of epithelial/endothelial
tyrosine kinase at tyrosine 40 (Etkp40) and transactivation of vascular endothelial growth factor receptor-2 (VEGFR2p1054−1059) leading to cell
proliferation/survival. Purple text refers to common effects in ACR and ccRCC and Red text refers to effects in ccRCC.
much better therapeutical approach would be a selective
blockade of TNFR1 in ACR and TNFR2 in ccRCC.
6. Conclusion
Experimental data from human organ culture and in in
vitro systems clearly demonstrate an association of TNFR2
with ACR and ccRCC, suggesting that this receptor may
play a crucial role in mediating cellular responses in these
disorders. Thus, new therapeutic strategies to either activate
TNFR2 signalling in ACR (to facilitate tubular regeneration)
or to selectively inhibit TNFR2 signalling in ccRCC (to halt
tumor growth/progression) may be a better approach in the
treatment of these conditions than global blockade of TNF.
Clearly, future clinical studies are warranted to address the
prognostic and therapeutic role of TNFR2 in clinical nephrol-
ogy.
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